The outcomes of clinical trials has encouraged the approval of Pemigatinib, an FGFR2 inhibitor, for previously treated patients with advanced metastatic CCA harboring FGFR2 fusions [9]. Here, FGFR2 is linked to cholangiocarcinoma.